Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

SK Bioscience (302440 KS): Strong Base Business and IDT Contribution Drive 2Q25 Performance

SK Bioscience (302440 KS): IDT Drives Strong 3Q Performance; Operating Loss Narrows

SK Bioscience (302440 KS): Base Business Revives; IDT Turnaround; Preparing for a Leap Toward

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-bioscience-co-ltd" target="_blank" data-smartkarma-citation="entities:31484:1" rel="noopener">SK Bioscience (302440 KS)</a> reported 1Q26 revenue of KRW169B, up 9% YoY, driven by both base business and IDT. Operating loss widened due to higher R&amp;D and non-recurring base effect.</li>
<li>Although short-term profitability was limited, SKBS is preparing to leap forward by investing for future growth. Excluding these investments, SKBS would have reported operating loss of KRW8B for 1Q26.</li>
<li>The company plans to expand its CDMO business centered on IDT while accelerating the development of core pipelines to prepare for full-scale growth in the global market.</li>
</ul>



SK Bioscience (302440 KS) reported 1Q26 revenue of KRW169B, up 9% YoY, driven by both base business and IDT. Operating loss widened due to higher R&amp;D and non-recurring base effect.
Although short-term profitability was limited, SKBS is preparing to leap forward by investing for future growth. Excluding these investments, SKBS would have reported operating loss of KRW8B for 1Q26.
The company plans to expand its CDMO business centered on IDT while accelerating the development of core pipelines to prepare for full-scale growth in the global market.


SKバイオサイエンス（302440 KS）：第1四半期はIDTを中心とした堅調な成長が見られたが、営業損失は拡大した。